A 0 1 0 1 O
subject 2 9 2 9 O
known 10 15 10 15 O
to 16 18 16 18 O
be 19 21 19 21 O
infected 22 30 22 30 O
with 31 35 31 35 O
human 36 41 36 41 B-chronic_disease
immunodeficiency 42 58 42 58 I-chronic_disease
virus 59 64 59 64 I-chronic_disease
( 65 66 65 66 I-chronic_disease
HIV 66 69 66 69 I-chronic_disease
) 69 70 69 70 I-chronic_disease
, 70 71 70 71 O
hepatitis 72 81 72 81 B-chronic_disease
B 82 83 82 83 I-chronic_disease
or 84 86 84 86 O
hepatitis 87 96 87 96 B-chronic_disease
C 97 98 97 98 I-chronic_disease
virus 99 104 99 104 I-chronic_disease

Any 0 3 105 108 O
infection 4 13 109 118 O
requiring 14 23 119 128 O
hospitalization 24 39 129 144 O
, 39 40 144 145 O
parenteral 41 51 146 156 O
antimicrobial 52 65 157 170 B-treatment
therapy 66 73 171 178 I-treatment
or 74 76 179 181 O
judged 77 83 182 188 O
to 84 86 189 191 O
be 87 89 192 194 O
opportunistic 90 103 195 208 O
by 104 106 209 211 O
the 107 110 212 215 O
investigator 111 123 216 228 O
within 124 130 229 235 O
the 131 134 236 239 O
6 135 136 240 241 B-upper_bound
months 137 143 242 248 I-upper_bound
prior 144 149 249 254 I-upper_bound
to 150 152 255 257 O
the 153 156 258 261 O
first 157 162 262 267 O
dose 163 167 268 272 O
of 168 170 273 275 O
study 171 176 276 281 O
drug 177 181 282 286 O

Any 0 3 287 290 O
treated 4 11 291 298 O
infections 12 22 299 309 O
within 23 29 310 316 O
2 30 31 317 318 B-upper_bound
weeks 32 37 319 324 I-upper_bound
of 38 40 325 327 O
baseline 41 49 328 336 O
visit 50 55 337 342 O

Chronic 0 7 343 350 B-chronic_disease
infections 8 18 351 361 I-chronic_disease

Fertile 0 7 362 369 O
male 8 12 370 374 B-gender
subjects 13 21 375 383 I-gender
and 22 25 384 387 I-gender
female 26 32 388 394 I-gender
subjects 33 41 395 403 I-gender
of 42 44 404 406 O
childbearing 45 57 407 419 O
potential 58 67 420 429 O
who 68 71 430 433 O
are 72 75 434 437 O
, 75 76 437 438 O
in 77 79 439 441 O
the 80 83 442 445 O
opinion 84 91 446 453 O
of 92 94 454 456 O
the 95 98 457 460 O
investigator 99 111 461 473 O
, 111 112 473 474 O
sexually 113 121 475 483 O
active 122 128 484 490 O
and 129 132 491 494 O
at 133 135 495 497 O
risk 136 140 498 502 O
for 141 144 503 506 O
pregnancy 145 154 507 516 B-pregnancy
with 155 159 517 521 O
their 160 165 522 527 O
partner(s 166 175 528 537 O
) 175 176 537 538 O
must 177 181 539 543 O
be 182 184 544 546 O
using 185 190 547 552 B-contraception_consent
a 191 192 553 554 I-contraception_consent
highly 193 199 555 561 I-contraception_consent
effective 200 209 562 571 I-contraception_consent
method 210 216 572 578 I-contraception_consent
of 217 219 579 581 I-contraception_consent
contraception 220 233 582 595 I-contraception_consent
as 234 236 596 598 O
outlined 237 245 599 607 O
in 246 248 608 610 O
this 249 253 611 615 O
protocol 254 262 616 624 O
throughout 263 273 625 635 O
the 274 277 636 639 O
study 278 283 640 645 O
and 284 287 646 649 O
for 288 291 650 653 O
at 292 294 654 656 O
least 295 300 657 662 O
28 301 303 663 665 B-lower_bound
days 304 308 666 670 I-lower_bound
after 309 314 671 676 O
the 315 318 677 680 O
last 319 323 681 685 O
dose 324 328 686 690 O
of 329 331 691 693 O
study 332 337 694 699 O
medication 338 348 700 710 O

History 0 7 711 718 O
of 8 10 719 721 O
recurrent 11 20 722 731 O
( 21 22 732 733 O
more 22 26 733 737 O
than 27 31 738 742 O
one 32 35 743 746 O
episode 36 43 747 754 O
) 43 44 754 755 O
herpes 45 51 756 762 B-chronic_disease
zoster 52 58 763 769 I-chronic_disease
or 59 61 770 772 O
disseminated 62 74 773 785 O
( 75 76 786 787 O
a 76 77 787 788 O
single 78 84 789 795 O
episode 85 92 796 803 O
) 92 93 803 804 O
herpes 94 100 805 811 O
zoster 101 107 812 818 O
or 108 110 819 821 O
disseminated 111 123 822 834 O
( 124 125 835 836 O
a 125 126 836 837 O
single 127 133 838 844 O
episode 134 141 845 852 O
) 141 142 852 853 O
herpes 143 149 854 860 B-chronic_disease
simplex 150 157 861 868 I-chronic_disease

Infections 0 10 869 879 B-chronic_disease

Pediatric 0 9 880 889 O
subjects 10 18 890 898 O
with 19 23 899 903 O
JIA 24 27 904 907 B-chronic_disease

Subjects 0 8 908 916 O
must 9 13 917 921 O
have 14 18 922 926 O
previously 19 29 927 937 O
completed 30 39 938 947 O
participation 40 53 948 961 O
in 54 56 962 964 O
a 57 58 965 966 O
qualifying 59 69 967 977 O
study 70 75 978 983 O
of 76 78 984 986 O
tofacitinib 79 90 987 998 B-treatment
for 91 94 999 1002 O
the 95 98 1003 1006 O
treatment 99 108 1007 1016 O
of 109 111 1017 1019 O
JIA 112 115 1020 1023 B-chronic_disease

Subjects 0 8 1024 1032 O
turning 9 16 1033 1040 O
18 17 19 1041 1043 B-lower_bound
years 20 25 1044 1049 I-lower_bound
of 26 28 1050 1052 O
age 29 32 1053 1056 B-age
during 33 39 1057 1063 O
participation 40 53 1064 1077 O
in 54 56 1078 1080 O
the 57 60 1081 1084 O
qualifying 61 71 1085 1095 O
/ 71 72 1095 1096 O
index 72 77 1096 1101 O
study 78 83 1102 1107 O
or 84 86 1108 1110 O
subsequently 87 99 1111 1123 O
will 100 104 1124 1128 O
be 105 107 1129 1131 O
eligible 108 116 1132 1140 O
for 117 120 1141 1144 O
participation 121 134 1145 1158 O
in 135 137 1159 1161 O
this 138 142 1162 1166 O
study 143 148 1167 1172 O

Subjects 0 8 1173 1181 O
who 9 12 1182 1185 O
have 13 17 1186 1190 O
required 18 26 1191 1199 O
earlier 27 34 1200 1207 O
discontinuation 35 50 1208 1223 O
of 51 53 1224 1226 O
treatment 54 63 1227 1236 B-treatment
in 64 66 1237 1239 O
a 67 68 1240 1241 O
qualifying 69 79 1242 1252 O
study 80 85 1253 1258 O
for 86 89 1259 1262 O
reasons 90 97 1263 1270 O
other 98 103 1271 1276 O
than 104 108 1277 1281 O
tofacitinib 109 120 1282 1293 B-treatment
related 121 128 1294 1301 O
serious 129 136 1302 1309 O
adverse 137 144 1310 1317 O
events 145 151 1318 1324 O
may 152 155 1325 1328 O
be 156 158 1329 1331 O
eligible 159 167 1332 1340 O

Systemic 0 8 1341 1349 B-chronic_disease
JIA 9 12 1350 1353 I-chronic_disease
( 13 14 1354 1355 I-chronic_disease
sJIA 14 18 1355 1359 I-chronic_disease
) 18 19 1359 1360 I-chronic_disease
with 20 24 1361 1365 O
active 25 31 1366 1372 O
systemic 32 40 1373 1381 O
features 41 49 1382 1390 O
other 50 55 1391 1396 O
than 56 60 1397 1401 O
active 61 67 1402 1408 O
joints 68 74 1409 1415 O
and 75 78 1416 1419 O
elevated 79 87 1420 1428 O
acute 88 93 1429 1434 O
phase 94 99 1435 1440 O
reactants 100 109 1441 1450 O
, 109 110 1450 1451 O
persistent 111 121 1452 1462 B-chronic_disease
oligoarthritis 122 136 1463 1477 I-chronic_disease
, 136 137 1477 1478 O
and 138 141 1479 1482 O
undifferentiated 142 158 1483 1499 B-chronic_disease
JIA 159 162 1500 1503 I-chronic_disease

The 0 3 1504 1507 O
subject 4 11 1508 1515 O
has 12 15 1516 1519 O
discontinued 16 28 1520 1532 O
disallowed 29 39 1533 1543 O
concomitant 40 51 1544 1555 O
medications 52 63 1556 1567 B-treatment
for 64 67 1568 1571 O
the 68 71 1572 1575 O
required 72 80 1576 1584 O
time 81 85 1585 1589 O
prior 86 91 1590 1595 O
to 92 94 1596 1598 O
the 95 98 1599 1602 O
first 99 104 1603 1608 O
dose 105 109 1609 1613 O
of 110 112 1614 1616 O
study 113 118 1617 1622 O
drug 119 123 1623 1627 O

aged 0 4 1628 1632 B-age
from 5 9 1633 1637 O
2 10 11 1638 1639 B-lower_bound
to 12 14 1640 1642 O
less 15 19 1643 1647 O
than 20 24 1648 1652 O
18 25 27 1653 1655 B-upper_bound
years 28 33 1656 1661 I-upper_bound

who 0 3 1662 1665 O
met 4 7 1666 1669 O
entry 8 13 1670 1675 O
criteria 14 22 1676 1684 O
for 23 26 1685 1688 O
the 27 30 1689 1692 O
qualifying 31 41 1693 1703 O
/ 41 42 1703 1704 O
index 42 47 1704 1709 O
study 48 53 1710 1715 O
and 54 57 1716 1719 O
in 58 60 1720 1722 O
the 61 64 1723 1726 O
opinion 65 72 1727 1734 O
of 73 75 1735 1737 O
the 76 79 1738 1741 O
investigator 80 92 1742 1754 O
have 93 97 1755 1759 O
sufficient 98 108 1760 1770 O
evidence 109 117 1771 1779 O
of 118 120 1780 1782 O
JIA 121 124 1783 1786 B-chronic_disease
disease 125 132 1787 1794 I-chronic_disease
activity 133 141 1795 1803 O
to 142 144 1804 1806 O
warrant 145 152 1807 1814 O
use 153 156 1815 1818 O
of 157 159 1819 1821 O
tofacitinib 160 171 1822 1833 B-treatment
as 172 174 1834 1836 O
a 175 176 1837 1838 O
DMARD 177 182 1839 1844 B-treatment

